Promega Madison Achieves ISO 14001 Certification for Environmental Management
6.5.2025 13:00:00 CEST | Business Wire | Press Release
Promega Corporation announced today that its headquarters in Madison, Wisconsin has achieved ISO 14001:2015 certification, an internationally recognized standard for environmental management systems. This certification reflects the biotechnology manufacturer’s longstanding commitment to environmental stewardship and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505641030/en/
Promega Madison has achieved ISO 14001:2015 certification for its environmental management system. Promega announced the certification in its annual Corporate Responsibility Report, which also features sustainability metrics and details on how the biotechnology manufacturer supports scientists, employees and communities.
“For more than 45 years, Promega has been dedicated to environmental management and sustainable practices within the life sciences industry,” says Jaime Dwight, Director, Environmental Health & Safety and Controlled Substances. “This certification embodies the effort we have invested in fostering a culture of environmental responsibility, ensuring environmental compliance and promoting continual improvement across our operations.”
Promega announced the certification in its 2025 Corporate Responsibility Report, published today on the company’s website. In addition to sustainability metrics, the report captures how Promega supports scientists, employees and communities.
ISO 14001:2015 Certification
ISO 14001:2015 is an internationally recognized standard for environmental management systems. It provides a framework for organizations to identify, manage, monitor and improve their environmental performance. The standard helps businesses reduce waste, comply with regulations and minimize their environmental impact while enhancing sustainability efforts.
To achieve this certification, Promega demonstrated a strong environmental management system including adherence to environmental compliance requirements, mitigating environmental impact of our operations, and leadership commitment to sustainable best practices. A thorough review by independent auditors confirmed the company’s efforts in these areas.
Examples of Promega environmental initiatives include:
- Innovative product design that incorporates green chemistry and ambient shipping stability
- A global commitment to sourcing 100% renewable electricity by the end of 2025
- Employee-driven programs such as plastic film collection and recycling
- On-site composting to support the company garden using food and landscaping waste
2025 Corporate Responsibility Report
Since 2008, Promega has issued an annual Corporate Responsibility Report detailing its progress in sustainability, product impact, employee well-being and community engagement. Highlights of this year’s report include:
- Supporting Young Scientists: The Promega Rising Researchers Scientific Innovation Awards honor exceptional PhD students around the world with resources, mentorship and a visit to Promega Madison.
- Giving Back to Communities: The Promega in Action initiative gives Madison-based employees the opportunity to receive up to 40 hours of paid time off to volunteer for a nonprofit organization of their choice.
- Investing in Research and Innovation: Promega invested 13.8% of its revenue in R&D in 2024, propelling advancements in drug discovery, bioluminescence imaging and cellular metabolism.
The 2025 Corporate Responsibility Report contains additional information on how Promega considers the United Nations Sustainable Development Goals (SDGs) in its practices and actions.
Read the latest Corporate Responsibility Report here.
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250505641030/en/
Contacts
Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom